Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Area of Science:

• Immunology
• Cancer Biology
• Metabolic Regulation

Background:

• Adoptive T-cell therapy (ACT) shows promise for cancer treatment but is limited by T-cell dysfunction and poor survival.
• Improving the persistence and effector function of infused T cells is critical for durable antitumor responses.

Purpose of the Study:

• To investigate the role of PIM kinases in T-cell metabolism and function.
• To determine if PIM kinase inhibition can enhance the efficacy of ACT for cancer treatment.

Main Methods:

• Studied PIM kinase function using genetic ablation and pharmacologic inhibition (PimKi) in T cells.
• Evaluated ACT efficacy in a murine melanoma model, combining T-cell transfer with PIM kinase inhibition, anti-PD1, or both.

Main Results:

• PIM kinase inhibition reduced glucose uptake and increased memory-associated gene expression in T cells.
• PIM kinase inhibition decreased CD38 expression, improving T-cell metabolic fitness.
• Combined ACT with PIM kinase inhibition significantly improved antitumor efficacy, further enhanced by anti-PD1.

Conclusions:

• PIM kinase inhibition improves T-cell function and persistence, enhancing ACT efficacy.
• Combination therapy of ACT, PIM kinase inhibition, and checkpoint blockade offers a potent strategy for cancer treatment.